HET0016

Research use only, not for human use.

HET0016 is a potent and selective 20-HETE synthase inhibitor (IC50s: 17.7 nM, 12.1 nM, and 20.6 nM for recombinant CYP4A1-, CYP4A2-, and CYP4A3-catalyzed 20-HETE synthesis) and a selective CYP450 inhibitor, shown to inhibit angiogenesis and tumor growth.

HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth.

HET0016 is a selective, non-competitive and irreversible inhibitor of CYP4A .HET0016 (100 μM; 24 hours, 48 hours) decreases migration and invasion of breast cancer metastatic cells .Cell Proliferation Assay Cell Line:MDA-MB-231 cells Concentration:100 μM Incubation Time:24 hours, 48 hours Result:Decreased migration and invasion of breast cancer metastatic cells

HET0016 (10 mg/kg/day; i.v.; for 3 weeks) reduces tumor volume and lung metastasis in an immunocompetent breast cancer mouse model.HET0016 reduces the metalloproteinases’ levels in the lungs via PI3K/AKT pathway in mice.HET0016 decreases expression of pro-inflammatory and growth factors and granulocytic MDSCs population in lung microenvironment.HET0016 protects BBB dysfunction after I/R by regulating the expression of MMP-9 and tight junction proteins.Animal Model:4–5 weeks female Balb/c mice (16-18 g) Dosage:10 mg/kg/day Administration:Intravenously; 5 days a week; for 3 weeks; starting from day 15 of tumor implantation Result:Reduced tumor volume and lung metastasis.

——

Others

Other Targets

Others

——

——

339068-25-6

206.28

C12H18N2O

>98% (HPLC)

In Vitro:?DCM : 12.5 mg/mL (60.60 mM; Ultrasonic) DMSO : 5 mg/mL (24.24 mM; Ultrasonic )

CCCCc1ccc(N=CNO)c(C)c1

——

(-20℃)

With Ice Pack

≥ 2 years